Originally from Lithuania, Artiom earned his undergraduate degree from the University of Oxford in 2012, followed by a PhD under the supervision of Professor Phil Baran at Scripps Research in 2017. Subsequently, Artiom joined Novartis BioMedical Research in Cambridge, MA, USA, as a medicinal chemist, where he contributed to oncology, immunology, and hematology programs, advancing multiple projects into clinical development. In 2023, Artiom was honored with the Young Investigator Award from the American Chemical Society for contributions to the first-in-class selective IKZF2 degrader, DKY709.

Artiom currently serves as a group leader in the Global Discovery Chemistry group at Novartis, focusing on prostate cancer research